Can we save a cookie?

We use cookies to enhance your experience on our website, target content and statistics. Read more about cookies

BacAttack - A stealth attack tool for preventing clinical drug resistance

Peter  Sommer-Larsen

Your Contact

Contact me

Indtast venligst et validt navn
Or your phone number
Thank you for your message
Vi beklager

På grund af en teknisk fejl kan din henvendelse desværre ikke modtages i øjeblikket. Du er velkommen til at skrive en mail til Send e-mail eller ringe til +45 72 20 15 09.

BacAttack - A stealth attack tool for preventing clinical drug resistance

Every year, outbreaks of clinical infections affect millions of patients worldwide. The present effective treatment for infections is large doses of systemically applied drugs. There is a high risk of recurring infections and biofilm formation for patients dependent on long term in-dwelling catheters and the extended dependency on antibiotics resulting in clinical drug resistance. Catheter-associated urinary tract infection (CAUTI) is one of the most important hospital acquired infections and responsible for 40 % of nosocomial infections.

The aims of the BacAttack project are to fill the gap of antimicrobial tools for long term catherisation, as well as resolving the issues concerning resistance development and combatting of multi-resistant strains. To this end, new materials with new antimicrobial strategies are developed to achieve localised, controlled, and long term drug delivery in catheters for the prevention of CAUTI.

We upgrade existing and future medical devices through a unique self-regenerating surface that prevents biofilm formation using a stealth attack mechanism. This is achieved by an interpenetrating polymer network (IPN) containing hydrogels that allows for long term release of a range of antimicrobial strategies. Local and site-specific treatment with long term effect instead of systemic treatment implies improved patient management and citizen welfare.

BacAttack is a four-year collaborative project funded by the EU, Grant Agreement no. 278998, under the FP7-HEALTH-2011 programme. The consortium consists of seven partners from five countries with specialties in material science, microbiology, physiology, and regulatory issues.

Please visit the project website for more information